Tuberculosis subunit vaccine development: Impact of physicochemical properties of mycobacterial test antigens

Vaccine

Volumn 25, Issue 9, 2007, Pages 1553-1566

  Sable, Suraj B ^a   Plikaytis, Bonnie B ^a   Shinnick, Thomas M ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Physicochemical properties; Subunit vaccine; Tuberculosis

Indexed keywords

AG85A ANTIGEN; AG85B ANTIGEN; ALANINE PROLINE RICH ANTIGEN; BCG VACCINE; CFP 10 ANTIGEN; CFP 11 ANTIGEN; CFP 29 ANTIGEN; CFP 31 ANTIGEN; CFP 32 ANTIGEN; CFP 6 ANTIGEN; CHAPERONIN; EARLY SECRETORY ANTIGENIC TARGET 6; HEPARIN BINDING HEMAGGLUTININ; LAMININ BINDING PROTEIN; MPB 70 ANTIGEN; MPB 83 PROTEIN; MPT 51 ANTIGEN; MPT 64 ANTIGEN; MTB12 ANTIGEN; MTB32A ANTIGEN; MTB8.4 ANTIGEN; MTB9.9 ANTIGEN; MTSP11 ANTIGEN; MTSP17 ANTIGEN; MYCOBACTERIUM ANTIGEN; PROTEIN DNAK; PST S1 PROTEIN; PST S3 PROTEIN; TB10.4 ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BACTERIAL IMMUNITY; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; BCG VACCINATION; DRUG STABILITY; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; IMMUNOREACTIVITY; MICROORGANISM DETECTION; MOLECULAR SIZE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW; TUBERCULOSIS;

ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; DRUG DESIGN; HUMANS; MICE; MICE, INBRED C57BL; MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS; T-LYMPHOCYTES; TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 33846376510     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.11.014     Document Type: Review

References (187)

1. Anon. Global tuberculosis control. WHO report 2002. Geneva, Switzerland: World Health Organization; 2002. p. 181.
2. Acheson D., Alleyne G.A., Casas J.A., Castillo-Salgado C., Barzach M., Braveman P., et al. Round table discussion. Health inequalities and the health of the poor. Bull World Health Organ 78 1 (2000) 75-85
3. Andersen P. TB vaccines: progress and problems. Trends Immunol 22 3 (2001) 160-168
4. Cole S.T., Brosch R., Parkhill J., Garnier T., Churcher C., Harris D., et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393 6685 (1998) 537-544
5. Shinnick T.M. Diagnostic test needs for evaluating antituberculosis vaccines. Clin Infect Dis 30 Suppl. 3 (2000) S276-S278
6. Horwitz M.A., Lee B.W., Dillon B.J., and Harth G. Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis. Proc Natl Acad Sci USA 92 5 (1995) 1530-1534
7. Sinha R.K., Verma I., and Khuller G.K. Immunobiological properties of a 30 kDa secretory protein of Mycobacterium tuberculosis H37Ra. Vaccine 15 6-7 (1997) 689-699
8. Sharma A.K., Verma I., Tewari R., and Khuller G.K. Adjuvant modulation of T-cell reactivity to 30-kDa secretory protein of Mycobacterium tuberculosis H37Rv and its protective efficacy against experimental tuberculosis. J Med Microbiol 48 8 (1999) 757-763
9. Andersen P., Askgaard D., Ljungqvist L., Bentzon M.W., and Heron I. T-cell proliferative response to antigens secreted by Mycobacterium tuberculosis. Infect Immun 59 4 (1991) 1558-1563
10. Orme I.M., Andersen P., and Boom W.H. T cell response to Mycobacterium tuberculosis. J Infect Dis 167 6 (1993) 1481-1497
11. Hovav A.H., Fishman Y., and Bercovier H. Gamma interferon and monophosphoryl lipid A-trehalose dicorynomycolate are efficient adjuvants for Mycobacterium tuberculosis multivalent acellular vaccine. Infect Immun 73 1 (2005) 250-257
12. Olsen A.W., Williams A., Okkels L.M., Hatch G., and Andersen P. Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model. Infect Immun 72 10 (2004) 6148-6150
13. Skeiky Y.A., Alderson M.R., Ovendale P.J., Guderian J.A., Brandt L., Dillon D.C., et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol 172 12 (2004) 7618-7628
14. Sable S.B., Verma I., Behera D., and Khuller G.K. Human immune recognition-based multicomponent subunit vaccines against tuberculosis. Eur Respir J 25 5 (2005) 902-910
15. Glyn Hewinson R. TB vaccines for the World. Tuberculosis (Edinb) 85 1-2 (2005) 1-6
16. Doherty T.M. Real world TB vaccines: clinical trials in TB-endemic regions. Vaccine 23 17-18 (2005) 2109-2114
17. Giri P.K., Sable S.B., Verma I., and Khuller G.K. Comparative evaluation of intranasal and subcutaneous route of immunization for development of mucosal vaccine against experimental tuberculosis. FMES Immunol Med Microbiol 45 1 (2005) 87-93
18. Ladel C.H., Daugelat S., and Kaufmann S.H. Immune response to Mycobacterium bovis bacille Calmette Guerin infection in major histocompatibility complex class I- and II-deficient knock-out mice: contribution of CD4 and CD8 T cells to acquired resistance. Eur J Immunol 25 2 (1995) 377-384
19. Casadevall A. Antibody-mediated immunity against intracellular pathogens: two-dimensional thinking comes full circle. Infect Immun 71 8 (2003) 4225-4228
20. Williams A., Reljic R., Naylor I., Clark S.O., Falero-Diaz G., Singh M., et al. Passive protection with immunoglobulin A antibodies against tuberculosis early infection of the lungs. Immunology 111 3 (2004) 328-333
21. Glatman-Freedman A. The role of antibody-mediated immunity in defense against Mycobacterium tuberculosis: advances toward a novel vaccine strategy. Tuberculosis (Edinb) 86 3-4 (2006) 191-197
22. Glatman-Freedman A., and Casadevall A. Serum therapy for tuberculosis revisited: reappraisal of the role of antibody-mediated immunity against Mycobacterium tuberculosis. Clin Microbiol Rev 11 3 (1998) 514-532
23. Kaufmann S.H. How can immunology contribute to the control of tuberculosis?. Nat Rev Immunol 1 1 (2001) 20-30
24. Agger E.M., and Andersen P. Tuberculosis subunit vaccine development: on the role of interferon-gamma. Vaccine 19 17-19 (2001) 2298-2302
25. Seah G.T., Scott G.M., and Rook G.A. Type 2 cytokine gene activation and its relationship to extent of disease in patients with tuberculosis. J Infect Dis 181 1 (2000) 385-389
26. Rook G.A., Hernandez-Pando R., Dheda K., and Teng Seah G. IL-4 in tuberculosis: implications for vaccine design. Trends Immunol 25 (2004) 483-488
27. Fischer K., Scotet E., Niemeyer M., Koebernick H., Zerrahn J., Maillet S., et al. Mycobacterial phosphatidylinositol mannoside is a natural antigen for CD1d-restricted T cells. Proc Natl Acad Sci USA 101 29 (2004) 10685-10690
28. Hiromatsu K., Dascher C.C., LeClair K.P., Sugita M., Furlong S.T., Brenner M.B., et al. Induction of CD1-restricted immune responses in guinea pigs by immunization with mycobacterial lipid antigens. J Immunol 169 1 (2002) 330-339
29. Welsh M.D., Kennedy H.E., Smyth A.J., Girvin R.M., Andersen P., and Pollock J.M. Responses of bovine WC1(+) gammadelta T cells to protein and nonprotein antigens of Mycobacterium bovis. Infect Immun 70 11 (2002) 6114-6120
30. Kaufmann S.H. Gamma/delta and other unconventional T lymphocytes: what do they see and what do they do?. Proc Natl Acad Sci USA 93 6 (1996) 2272-2279
31. Rojas R.E., Torres M., Fournie J.J., Harding C.V., and Boom W.H. Phosphoantigen presentation by macrophages to Mycobacterium tuberculosis-reactive Vgamma9Vdelta2+ T cells: modulation by chloroquine. Infect Immun 70 8 (2002) 4019-4027
32. Behr-Perst S.I., Munk M.E., Schaberg T., Ulrichs T., Schulz R.J., and Kaufmann S.H. Phenotypically activated gammadelta T lymphocytes in the peripheral blood of patients with tuberculosis. J Infect Dis 180 1 (1999) 141-149
33. Kaufmann S.H. Recent findings in immunology give tuberculosis vaccines a new boost. Trends Immunol 26 12 (2005) 660-667
34. Boesen H., Jensen B.N., Wilcke T., and Andersen P. Human T-cell responses to secreted antigen fractions of Mycobacterium tuberculosis. Infect Immun 63 4 (1995) 1491-1497
35. Sable S.B., Kumar R., Kalra M., Verma I., Khuller G.K., Dobos K., et al. Peripheral blood and pleural fluid mononuclear cell responses of human models of immunity to tuberculosis against low molecular mass secretory polypeptides of Mycobacterium tuberculosis. Infect Immun 73 (2005) 3547-3558
36. Weldingh K., Rosenkrands I., Jacobsen S., Rasmussen P.B., Elhay M.J., and Andersen P. Two-dimensional electrophoresis for analysis of Mycobacterium tuberculosis culture filtrate and purification and characterization of six novel proteins. Infect Immun 66 8 (1998) 3492-3500
37. Andersen P., Andersen A.B., Sorensen A.L., and Nagai S. Recall of long-lived immunity to Mycobacterium tuberculosis infection in mice. J Immunol 154 7 (1995) 3359-3372
38. Brandt L., Oettinger T., Holm A., Andersen A.B., and Andersen P. Key epitopes on the ESAT-6 antigen recognized in mice during the recall of protective immunity to Mycobacterium tuberculosis. J Immunol 157 8 (1996) 3527-3533
39. Sable S.B., Verma I., and Khuller G.K. Multicomponent antituberculous subunit vaccine based on immunodominant antigens of Mycobacterium tuberculosis. Vaccine 23 32 (2005) 4175-4184
40. Barclay W.R., Anacker R., Brehmer W., and Ribi E. Effects of oil-treated mycobacterial cell walls on the organs of mice. J Bacteriol 94 5 (1967) 1736-1745
41. Chugh I.B., and Khuller G.K. Immunoprotective behaviour of liposome entrapped cell wall subunit of Mycobacterium tuberculosis against experimental tuberculous infection in mice. Eur Respir J 6 6 (1993) 811-815
42. Orme I.M. Induction of nonspecific acquired resistance and delayed-type hypersensitivity, but not specific acquired resistance in mice inoculated with killed mycobacterial vaccines. Infect Immun 56 12 (1988) 3310-3312
43. Dhiman N., and Khuller G.K. Protective efficacy of mycobacterial 71-kDa cell wall associated protein using poly(dl-lactide-co-glycolide) microparticles as carrier vehicles. FEMS Immunol Med Microbiol 21 1 (1998) 19-28
44. Hamasur B., Haile M., Pawlowski A., Schroder U., Williams A., Hatch G., et al. Mycobacterium tuberculosis arabinomannan-protein conjugates protect against tuberculosis. Vaccine 21 25-26 (2003) 4081-4093
45. Dascher C.C., Hiromatsu K., Xiong X., Morehouse C., Watts G., Liu G., et al. Immunization with a mycobacterial lipid vaccine improves pulmonary pathology in the guinea pig model of tuberculosis. Int Immunol 15 8 (2003) 915-925
46. Singh A.P., and Khuller G.K. Induction of immunity against experimental tuberculosis with mycobacterial mannophosphoinositides encapsulated in liposomes containing lipid A. FEMS Immunol Med Microbiol 8 2 (1994) 119-126
47. Kim H.J., Jo E.K., Park J.K., Lim J.H., Min D., and Paik T.H. Isolation and partial characterisation of the Triton X-100 solubilised protein antigen from Mycobacterium tuberculosis. J Med Microbiol 48 6 (1999) 585-591
48. Mehrotra J., Mittal A., Rastogi A.K., Jaiswal A.K., Bhandari N.K., and Sinha S. Antigenic definition of plasma membrane proteins of Bacillus Calmette-Guerin: predominant activation of human T cells by low-molecular-mass integral proteins. Scand J Immunol 50 4 (1999) 411-419
49. Pancholi P., Vinayak V.K., and Khuller G.K. Immunogenicity of ribonucleic acid-protein fraction of Mycobacterium tuberculosis encapsulated in liposomes. J Med Microbiol 29 2 (1989) 131-138
50. Miyazaki C., Ohara N., Yukitake H., Kinomoto M., Matsushita K., Matsumoto S., et al. Host immune responses to ribosome, ribosomal proteins, and RNA from Mycobacterium bovis bacille de Calmette-Guerin. Vaccine 17 3 (1999) 245-251
51. Andersen P., and Doherty T.M. TB subunit vaccines-putting the pieces together. Microb Infect 7 5-6 (2005) 911-921
52. Tizard I.R. Antigens and antigenicity. Immunology an introduction (1994), Sunders College Publishing/Harcourt Brace College Publishers p. 9-49
53. Pisterer C., Mihailescu D., Smith J.C., and Reed J. A common pharmacophoric footprint for AIDS vaccine design. J Med Chem 47 15 (2004) 3723-3729
54. Lee C.J., Banks S.D., and Li J.P. Virulence, immunity, and vaccine related to Streptococcus pneumoniae. Crit Rev Microbiol 18 2 (1991) 89-114
55. Yang Y.P., Munson Jr. R.S., Grass S., Chang P., Harkness R.E., Gisonni L., et al. Effect of lipid modification on the physicochemical, structural, antigenic and immunoprotective properties of Haemophilus influenzae outer membrane protein P6. Vaccine 15 9 (1997) 976-987
56. Andersen P., and Heron I. Simultaneous electroelution of whole SDS-polyacrylamide gels for the direct cellular analysis of complex protein mixtures. J Immunol Methods 161 1 (1993) 29-39
57. Bassey E.O., Life P.F., Catty D., Gaston J.S., and Kumararatne D.S. T-cell response to mycobacterial proteins: a comparative study of tuberculous and control immunoblots of Mycobacterium tuberculosis and M. bovis BCG. Tuber Lung Dis 77 2 (1996) 146-153
58. Sorensen A.L., Nagai S., Houen G., Andersen P., and Andersen A.B. Purification and characterization of a low-molecular-mass T-cell antigen secreted by Mycobacterium tuberculosis. Infect Immun 63 5 (1995) 1710-1717
59. Haslov K., Andersen A., Nagai S., Gottschau A., Sorensen T., and Andersen P. Guinea pig cellular immune responses to proteins secreted by Mycobacterium tuberculosis. Infect Immun 63 3 (1995) 804-810
60. Pollock J.M., and Andersen P. Predominant recognition of the ESAT-6 protein in the first phase of infection with Mycobacterium bovis in cattle. Infect Immun 65 7 (1997) 2587-2592
61. Demissie A., Ravn P., Olobo J., Doherty T.M., Eguale T., Geletu M., et al. T-cell recognition of Mycobacterium tuberculosis culture filtrate fractions in tuberculosis patients and their household contacts. Infect Immun 67 11 (1999) 5967-5971
62. Bhaskar S., Khanna S.P., and Mukherjee R. Isolation, purification and immunological characterization of novel low molecular weight protein antigen CFP 6 from culture filtrate of M. tuberculosis. Vaccine 18 25 (2000) 2856-2866
63. Mustafa A.S., Shaban F.A., Al-Attiyah R., Abal A.T., El-Shamy A.M., Andersen P., et al. Human Th1 cell lines recognize the Mycobacterium tuberculosis ESAT-6 antigen and its peptides in association with frequently expressed HLA class II molecules. Scand J Immunol 57 2 (2003) 125-134
64. Ravn P., Demissie A., Eguale T., Wondwosson H., Lein D., Amoudy H.A., et al. Human T cell responses to the ESAT-6 antigen from Mycobacterium tuberculosis. J Infect Dis 179 3 (1999) 637-645
65. Mustafa A.S., Oftung F., Amoudy H.A., Madi N.M., Abal A.T., Shaban F., et al. Multiple epitopes from the Mycobacterium tuberculosis ESAT-6 antigen are recognized by antigen-specific human T cell lines. Clin Infect Dis 30 Suppl. 3 (2000) S201-S205
66. Sable S.B., Kaur S., Verma I., and Khuller G.K. Immunodominance of low molecular weight secretory polypeptides of Mycobacterium tuberculosis to induce cytotoxic T-lymphocyte response. Vaccine 23 41 (2005) 4947-4954
67. Wilkinson K.A., Belisle J.T., Mincek M., Wilkinson R.J., and Toossi Z. Enhancement of the human T cell response to culture filtrate fractions of Mycobacterium tuberculosis by microspheres. J Immunol Methods 235 1-2 (2000) 1-9
68. Lewinsohn D.M., Grotzke J.E., Heinzel A.S., Zhu L., Ovendale P.J., Johnson M., et al. Secreted proteins from Mycobacterium tuberculosis gain access to the cytosolic MHC class-I antigen-processing pathway. J Immunol 177 1 (2006) 437-442
69. Balaji K.N., and Boom W.H. Processing of Mycobacterium tuberculosis bacilli by human monocytes for CD4+ alphabeta and gammadelta T cells: role of particulate antigen. Infect Immun 66 1 (1998) 98-106
70. Tsukaguchi K., Balaji K.N., and Boom W.H. CD4+ alpha beta T cell and gamma delta T cell responses to Mycobacterium tuberculosis. Similarities and differences in Ag recognition, cytotoxic effector function, and cytokine production. J Immunol 154 4 (1995) 1786-1796
71. Skjot R.L., Oettinger T., Rosenkrands I., Ravn P., Brock I., Jacobsen S., et al. Comparative evaluation of low-molecular-mass proteins from Mycobacterium tuberculosis identifies members of the ESAT-6 family as immunodominant T-cell antigens. Infect Immun 68 1 (2000) 214-220
72. Skjot R.L., Brock I., Arend S.M., Munk M.E., Theisen M., Ottenhoff T.H., et al. Epitope mapping of the immunodominant antigen TB10.4 and the two homologous proteins TB10.3 and TB12.9, which constitute a subfamily of the esat-6 gene family. Infect Immun 70 10 (2002) 5446-5453
73. Coler R.N., Campos-Neto A., Ovendale P., Day F.H., Fling S.P., Zhu L., et al. Vaccination with the T cell antigen Mtb 8. 4 protects against challenge with Mycobacterium tuberculosis. J Immunol 166 10 (2001) 6227-6235
74. Lim J.H., Kim H.J., Lee K.S., Jo E.K., Song C.H., Jung S.B., et al. Identification of the new T-cell-stimulating antigens from Mycobacterium tuberculosis culture filtrate. FEMS Microbiol Lett 232 1 (2004) 51-59
75. Webb J.R., Vedvick T.S., Alderson M.R., Guderian J.A., Jen S.S., Ovendale P.J., et al. Molecular cloning, expression, and immunogenicity of MTB12, a novel low-molecular-weight antigen secreted by Mycobacterium tuberculosis. Infect Immun 66 9 (1998) 4208-4214
76. Wieles B., Nagai S., Wiker H.G., Harboe M., and Ottenhoff T.H. Identification and functional characterization of thioredoxin of Mycobacterium tuberculosis. Infect Immun 63 12 (1995) 4946-4948
77. Caccamo N., Meraviglia S., La Mendola C., Bosze S., Hudecz F., Ivanyi J., et al. Characterization of HLA-DR- and TCR-binding residues of an immunodominant and genetically permissive peptide of the 16-kDa protein of Mycobacterium tuberculosis. Eur J Immunol 34 8 (2004) 2220-2229
78. Aagaard C., Brock I., Olsen A., Ottenhoff T.H., Weldingh K., and Andersen P. Mapping immune reactivity toward Rv2653 and Rv2654: two novel low-molecular-mass antigens found specifically in the Mycobacterium tuberculosis complex. J Infect Dis 189 5 (2004) 812-819
79. Lalvani A., Nagvenkar P., Udwadia Z., Pathan A.A., Wilkinson K.A., Shastri J.S., et al. Enumeration of T cells specific for RD1-encoded antigens suggests a high prevalence of latent Mycobacterium tuberculosis infection in healthy urban Indians. J Infect Dis 183 3 (2001) 469-477
80. Leyten E.M.S., Lin M.Y., Franken K.L.M.C., Friggen A.H., Prins C., van Meijgaarden K.E., et al. Human T-cell responses to 25 novel antigens encoded by genes of the dormancy regulon of Mycobacterium tuberculosis. Microbes Infect 8 8 (2006) 2052-2060
81. Arend S.M., Andersen P., van Meijgaarden K.E., Skhot R.L., Subronto Y.W., van Dissel J.T., et al. Detection of active tuberculosis infection by T cell responses to early-secreted antigenic target 6-kDa protein and culture filtrate protein 10. J Infect Dis 181 5 (2000) 1850-1854
82. Pai M., Joshi R., Dogra S., Mendiratta D.K., Narang P., Dheda K., et al. Persistently elevated T cell interferon-gamma responses after treatment for latent tuberculosis infection among health care workers in India: a preliminary report. J Occup Med Toxicol 23 1 (2006) 7
83. Mehrotra J., Mittal A., Dhindsa M.S., and Sinha S. Fractionation of mycobacterial integral membrane proteins by continuous elution SDS-PAGE reveals the immunodominance of low molecular weight subunits for human T cells. Clin Exp Immunol 109 3 (1997) 446-450
84. Rowland S.S., Ruckert J.L., and Cummings P.J. Low molecular mass protein patterns in mycobacterial culture filtrates and purified protein derivatives. FEMS Immunol Med Microbiol 23 1 (1999) 21-25
85. Pais T.F., Cunha J.F., and Appelberg R. Antigen specificity of T-cell response to Mycobacterium avium infection in mice. Infect Immun 68 8 (2000) 4805-4810
86. Olsen I., and Storset A.K. Innate IFN-gamma production in cattle in response to MPP14, a secreted protein from Mycobacterium avium subsp. Paratuberculosis. Scand J Immunol 54 3 (2001) 306-313
87. Geluk A., van Meijgaarden K.E., Franken K.L., Subronto Y.W., Wieles B., Arend S.M., et al. Identification and characterization of the ESAT-6 homologue of Mycobacterium leprae and T-cell cross-reactivity with Mycobacterium tuberculosis. Infect Immun 70 5 (2002) 2544-2548
88. Geluk A., van Meijgaarden K.E., Franken K.L., Wieles B., Arend S.M., Faber W.R., et al. Immunological crossreactivity of the Mycobacterium leprae CFP-10 with its homologue in Mycobacterium tuberculosis. Scand J Immunol 59 1 (2004) 66-70
89. Laal S., Samanich K.M., Sonnenberg M.G., Zolla-Pazner S., Phadtare J.M., and Belisle J.T. Human humoral responses to antigens of Mycobacterium tuberculosis: immunodominance of high-molecular-mass antigens. Clin Diagn Lab Immunol 4 1 (1997) 49-56
90. Laal S., Samanich K.M., Sonnenberg M.G., Belisle J.T., O'Leary J., Simberkoff M.S., et al. Surrogate marker of preclinical tuberculosis in human immunodeficiency virus infection: antibodies to an 88-kDa secreted antigen of Mycobacterium tuberculosis. J Infect Dis 176 1 (1997) 133-143
91. Samanich K.M., Belisle J.T., Sonnenberg M.G., Keen M.A., Zolla-Pazner S., and Laal S. Delineation of human antibody responses to culture filtrate antigens of Mycobacterium tuberculosis. J Infect Dis 178 5 (1998) 1534-1538
92. Brandt L., Elhay M., Rosenkrands I., Lindblad E.B., and Andersen P. ESAT-6 subunit vaccination against Mycobacterium tuberculosis. Infect Immun 68 2 (2000) 791-795
93. Spencer J.S., Kim H.J., Marques A.M., Gonzalez-Juarerro M., Lima M.C., Vissa V.D., et al. Comparative analysis of B- and T-cell epitopes of Mycobacterium leprae and Mycobacterium tuberculosis culture filtrate protein 10. Infect Immun 72 6 (2004) 3161-3170
94. Olsen A.W., Hansen P.R., Holm A., and Andersen P. Efficient protection against Mycobacterium tuberculosis by vaccination with a single subdominant epitope from the ESAT-6 antigen. Eur J Immunol 30 6 (2000) 1724-1732
95. D'Souza S., Rosseels V., Romano M., Tanghe A., Denis O., Jurion F., et al. Mapping of murine Th1 helper T-Cell epitopes of mycolyl transferases Ag85A, Ag85B, and Ag85C from Mycobacterium tuberculosis. Infect Immun 71 1 (2003) 483-493
96. Launois P., DeLeys R., Niang M.N., Drowart A., Andrien M., Dierckx P., et al. T-cell-epitope mapping of the major secreted mycobacterial antigen Ag85A in tuberculosis and leprosy. Infect Immun 62 9 (1994) 3679-3687
97. Andersen P. Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins. Infect Immun 62 6 (1994) 2536-2544
98. Dietrich J., Aagaard C., Leah R., Olsen A.W., Stryhn A., Doherty T.M., et al. Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. J Immunol 174 10 (2005) 6332-6339
99. Hervas-Stubbs S., Majlessi L., Simsova M., Morova J., Rojas M.J., Nouze C., et al. High frequency of CD4+ T cells specific for the TB10. 4 protein correlates with protection against Mycobacterium tuberculosis infection. Infect Immun 74 6 (2006) 3396-3407
100. Alderson M.R., Bement T., Day C.H., Zhu L., Molesh D., Skeiky Y.A., et al. Expression cloning of an immunodominant family of Mycobacterium tuberculosis antigens using human CD4(+) T cells. J Exp Med 191 3 (2000) 551-560
101. Al-Attiyah R., Mustafa A.S., Abal A.T., El-Shamy A.S., Dalemans W., and Skeiky Y.A. In vitro cellular immune responses to complex and newly defined recombinant antigens of Mycobacterium tuberculosis. Clin Exp Immunol 138 1 (2004) 139-144
102. Grover A., Ahmed M.F., Singh B., Verma I., Sharma P., and Khuller G.K. A multivalent combination of experimental antituberculosis DNA vaccines based on Ag85B and regions of difference antigens. Microbes Infect 8 9-10 (2006) 2390-2399
103. Rosenkrands I., Weldingh K., Ravn P., Brandt L., Hojrup P., Rasmussen P.B., et al. Differential T-cell recognition of native and recombinant Mycobacterium tuberculosis GroES. Infect Immun 67 11 (1999) 5552-5558
104. Feng C.G., Blanchard T.J., Smith G.L., Hill A.V., and Britton W.J. Induction of CD8+ T-lymphocyte responses to a secreted antigen of Mycobacterium tuberculosis by an attenuated vaccinia virus. Immunol Cell Biol 79 6 (2001) 569-575
105. Delogu G., Howard A., Collins F.M., and Morris S.L. DNA vaccination against tuberculosis: expression of a ubiquitin-conjugated tuberculosis protein enhances antimycobacterial immunity. Infect Immun 68 6 (2000) 3097-3102
106. Miki K., Nagata T., Tanaka T., Kim Y.H., Uchijima M., Ohara N., et al. Induction of protective cellular immunity against Mycobacterium tuberculosis by recombinant attenuated self-destructing Listeria monocytogenes strains harboring eukaryotic expression plasmids for antigen 85 complex and MPB/MPT51. Infect Immun 72 4 (2004) 2014-2021
107. Rosenkrands I., Rasmussen P.B., Carnio M., Jacobsen S., Theisen M., and Andersen P. Identification and characterization of a 29-kilodalton protein from Mycobacterium tuberculosis culture filtrate recognized by mouse memory effector cells. Infect Immun 66 6 (1998) 2728-2735
108. Horwitz M.A., Harth G., Dillon B.J., and Maslesa-Galic S. Enhancing the protective efficacy of Mycobacterium bovis BCG vaccination against tuberculosis by boosting with the Mycobacterium tuberculosis major secretory protein. Infect Immun 73 8 (2005) 4676-4683
109. McShane H., Pathan A.A., Sander C.R., Goonetilleke N.P., Fletcher H.A., and Hill A.V. Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials. Tuberculosis (Edinb) 85 1-2 (2005) 47-52
110. Santosuosso M., McCormick S., Zhang X., Zganiacz A., and Xing Z. Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis. Infect Immun 74 8 (2006) 4634-4643
111. Skeiky Y.A., Lodes M.J., Guderian J.A., Mohamath R., Bement T., Alderson M.R., et al. Cloning, expression, and immunological evaluation of two putative secreted serine protease antigens of Mycobacterium tuberculosis. Infect Immun 67 8 (1999) 3998-4007
112. Brandt L., Skeiky Y.A., Alderson M.R., Lobet Y., Dalemans W., Turner O.C., et al. The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect Immun 72 11 (2004) 6622-6632
113. Ferraz J.C., Stavropoulos E., Yang M., Coade S., Espitia C., Lowrie D.B., et al. A heterologous DNA priming-Mycobacterium bovis BCG boosting immunization strategy using mycobacterial Hsp70, Hsp65, and Apa antigens improves protection against tuberculosis in mice. Infect Immun 72 12 (2004) 6945-6950
114. Skeiky Y.A., and Sadoff J.C. Advances in tuberculosis vaccine strategies. Nat Rev Microbiol 4 6 (2006) 469-476
115. Majlessi L., Simsova M., Jarvis Z., Brodin P., Rojas M.J., Bauche C., et al. An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis. Infect Immun 74 4 (2006) 2128-2137
116. Rigano M.M., Dreitz S., Kipnis A.P., Izzo A.A., and Walmsley A.M. Oral immunogenicity of a plant-made, subunit, tuberculosis vaccine. Vaccine 24 5 (2006) 691-695 30
117. Holten-Andersen L., Doherty T.M., Korsholm K.S., and Andersen P. Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines. Infect Immun 72 3 (2004) 1608-1617
118. Zaks K., Jordan M., Guth A., Sellins K., Kedl R., Izzo A., et al. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J Immunol 176 12 (2006) 7335-7345 15
119. Agger E.M., Rosenkrands I., Olsen A.W., Hatch G., Williams A., Kritsch C., et al. Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31. Vaccine 24 26 (2006) 5452-5460
120. Grover A., Ahmed M.F., Verma I., Sharma P., and Khuller G.K. Expression and purification of the Mycobacterium tuberculosis complex-restricted antigen CFP21 to study its immunoprophylactic potential in mouse model. Protein Expr Purif 48 2 (2006) 274-280
121. Yeremeev V.V., Lyadova I.V., Nikonenko B.V., Apt A.S., Abou-Zeid C., Inwald J., et al. The 19-kD antigen and protective immunity in a murine model of tuberculosis. Clin Exp Immunol 120 2 (2000) 274-279
122. Vordermeier H.M., Chambers M.A., Cockle P.J., Whelan A.O., Simmons J., and Hewinson R.G. Correlation of ESAT-6-specific gamma interferon production with pathology in cattle following Mycobacterium bovis BCG vaccination against experimental bovine tuberculosis. Infect Immun 70 (2002) 3026-3032
123. Doytchinova I.A., and Flower D.R. Toward the quantitative prediction of T-cell epitopes: coMFA and coMSIA studies of peptides with affinity for the class I MHC molecule HLA-A*0201. J Med Chem 44 22 (2001) 3572-3581
124. Harboe M., Malin A.S., Dockrell H.S., Wiker H.G., Ulvund G., Holm A., et al. B-cell epitopes and quantification of the ESAT-6 protein of Mycobacterium tuberculosis. Infect Immun 66 2 (1998) 717-723
125. Moody D.B., Young D.C., Cheng T.Y., Rosat J.P., Roura-Mir C., O'Connor P.B., et al. T cell activation by lipopeptide antigens. Science 303 5657 (2004) 527-531
126. Amara R.R., Shanti S., and Satchidanandam V. Characterization of novel immunodominant antigens of Mycobacterium tuberculosis. Microbiology 144 Pt 5 (1998) 1197-1203
127. Verma I., Yadav D., Sharma S., Sinha R., and Khuller G.K. Immunoreactivity of mycobacterial 70 kDa protein in different physico-chemical forms. Indian J Med Res 106 (1997) 13-15
128. Ortalo-Magne A., Lemassu A., Laneelle M.A., Bardou F., Silve G., Gounon P., et al. Identification of the surface-exposed lipids on the cell envelopes of Mycobacterium tuberculosis and other mycobacterial species. J Bacteriol 178 2 (1996) 456-461
129. Ronning D.R., Vissa V., Besra G.S., Belisle J.T., and Sacchettini J.C. Mycobacterium tuberculosis antigen 85A and 85C structures confirm binding orientation and conserved substrate specificity. J Biol Chem 279 35 (2004) 36771-36777
130. Ortalo-Magne A., Dupont M.A., Lemassu A., Andersen A.B., Gounon P., and Daffe M. Molecular composition of the outermost capsular material of the tubercle bacillus. Microbiology 141 Pt 7 (1995) 1609-1620
131. Ortalo-Magne A., Andersen A.B., and Daffe M. The outermost capsular arabinomannans and other mannoconjugates of virulent and avirulent tubercle bacilli. Microbiology 142 Pt 4 (1996) 927-935
132. Rousseau C., Neyrolles O., Bordat Y., Giroux S., Sirakova T.D., Prevost M.C., et al. Deficiency in mycolipenate- and mycosanoate-derived acyltrehaloses enhances early interactions of Mycobacterium tuberculosis with host cells. Cell Microbiol 5 6 (2003) 405-415
133. Schlesinger L.S., Kaufman T.M., Iyer S., Hull S.R., and Marchiando L.K. Differences in mannose receptor-mediated uptake of lipoarabinomannan from virulent and attenuated strains of Mycobacterium tuberculosis by human macrophages. J Immunol 157 10 (1996) 4568-4575
134. Ehlers M.R., and Daffe M. Interactions between Mycobacterium tuberculosis and host cells: are mycobacterial sugars the key?. Trends Microbiol 6 8 (1998) 328-335
135. Brennan P.J. Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis. Tuberculosis (Edinb) 83 1-3 (2003) 91-97
136. Nagai S., Wiker H.G., Harboe M., and Kinomoto M. Isolation and partial characterization of major protein antigens in the culture fluid of Mycobacterium tuberculosis. Infect Immun 59 1 (1991) 372-382
137. Sugden E.A., Stilwell K., Watson D.C., Rohonczy E.B., and Martineau P. Purification of Mycobacterium bovis BCG Tokyo antigens by chromatofocusing, lectin-affinity chromatography, and hydrophobic interaction chromatography. Clin Diagn Lab Immunol 3 5 (1996) 541-546
138. Denis O., Lozes E., and Huygen K. Induction of cytotoxic T-cell responses against culture filtrate antigens in Mycobacterium bovis bacillus Calmette-Guerin-infected mice. Infect Immun 65 2 (1997) 676-684
139. Sable SB. Studies on immunoreactivity of early secretory antigens of Mycobacterium bovis AN-5. MVSc thesis. Izatnagar, India: Division of Immunology, Indian Veterinary Research Institute; 1998.
140. Huygen K., Content J., Denis O., Montgomery D.L., Yawman A.M., Deck R.R., et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat Med 2 8 (1996) 893-898
141. Manca C., Lyashchenko K., Colangeli R., and Gennaro M.L. MTC28a, novel 28-kilodalton proline-rich secreted antigen specific for the Mycobacterium tuberculosis complex. Infect Immun 65 12 (1997) 4951-4957
142. Devi K.R., Kumar K.S., Ramalingam B., and Alamelu R. Purification and characterization of three immunodominant proteins (38, 30, and 16 kDa) of Mycobacterium tuberculosis. Protein Expr Purif 24 2 (2002) 188-195
143. Mehrotra J., Bisht D., Tiwari V.D., and Sinha S. Serological distinction of integral plasma membrane proteins as a class of mycobacterial antigens and their relevance for human T cell activation. Clin Exp Immunol 102 3 (1995) 626-634
144. Gu S., Chen J., Dobos K.M., Bradbury E.M., Belisle J.T., and Chen X. Comprehensive proteomic profiling of the membrane constituents of a Mycobacterium tuberculosis strain. Mol Cell Proteomics 2 12 (2003) 1284-1296
145. Germain R.N. MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell 76 2 (Jan 28, 1994) 287-299
146. Dhiman N., and Khuller G.K. Immunoreactivity of peptides generated by limited proteolysis of 71-kDa cell wall protein of Mycobacterium tuberculosis H37Ra using PLG-microparticles. Lett Appl Microbiol 30 5 (2000) 345-350
147. Kaufmann S.H. Heat shock proteins and the immune response. Immunol Today 11 4 (1990) 129-136
148. Tasneem S., Islam N., and Ali R. Crossreactivity of SLE autoantibodies with 70 kDa heat shock proteins of Mycobacterium tuberculosis. Microbiol Immunol 45 12 (2001) 841-846
149. Turner O.C., Roberts A.D., Frank A.A., Phalen S.W., McMurray D.M., Content J., et al. Lack of protection in mice and necrotizing bronchointerstitial pneumonia with bronchiolitis in guinea pigs immunized with vaccines directed against the hsp60 molecule of Mycobacterium tuberculosis. Infect Immun 68 6 (2000) 3674-3679
150. Hu Y., and Coates A.R. Transcription of the stationary-phase-associated hspX gene of Mycobacterium tuberculosis is inversely related to synthesis of the 16-kilodalton protein. J Bacteriol 181 5 (1999) 1380-1387
151. Mao Q., and Chang Z. Site-directed mutation on the only universally conserved residue Leu122 of small heat shock protein Hsp16.3. Biochem Biophys Res Commun 289 5 (2001) 1257-1261
152. Tullius M.V., Harth G., and Horwitz M.A. High extracellular levels of Mycobacterium tuberculosis glutamine synthetase and superoxide dismutase in actively growing cultures are due to high expression and extracellular stability rather than to a protein-specific export mechanism. Infect Immun 69 10 (2001) 6348-6363
153. Herrmann J.L., O'Gaora P., Gallagher A., Thole J.E., and Young D.B. Bacterial glycoproteins: a link between glycosylation and proteolytic cleavage of a 19 kDa antigen from Mycobacterium tuberculosis. EMBO J 15 14 (1996) 3547-3554
154. Pethe K., Bifani P., Drobecq H., Sergheraert C., Debrie A.S., Locht C., et al. Mycobacterial heparin-binding hemagglutinin and laminin-binding protein share antigenic methyllysines that confer resistance to proteolysis. Proc Natl Acad Sci USA 99 16 (2002) 10759-10764
155. Edwards K.M., Cynamon M.H., Voladri R.K., Hager C.C., DeStefano M.S., Tham K.T., et al. Iron-cofactored superoxide dismutase inhibits host responses to Mycobacterium tuberculosis. Am J Respir Crit Care Med 164 12 (2001) 2213-2219
156. Delogu G., Li A., Repique C., Collins F., and Morris S.L. DNA vaccine combinations expressing either tissue plasminogen activator signal sequence fusion proteins or ubiquitin-conjugated antigens induce sustained protective immunity in a mouse model of pulmonary tuberculosis. Infect Immun 70 1 (2002) 292-302
157. Espitia C., and Mancilla R. Identification, isolation and partial characterization of Mycobacterium tuberculosis glycoprotein antigens. Clin Exp Immunol 77 3 (1989) 378-383
158. Young D.B., and Garbe T.R. Lipoprotein antigens of Mycobacterium tuberculosis. Res Microbiol 142 1 (1991) 55-65
159. Espitia C., Espinosa R., Saavedra R., Mancilla R., Romain F., Laqueyrerie A., et al. Antigenic and structural similarities between Mycobacterium tuberculosis 50- to 55-kilodalton and Mycobacterium bovis BCG 45- to 47-kilodalton antigens. Infect Immun 63 2 (1995) 580-584
160. Fifis T., Costopoulos C., Radford A.J., Bacic A., and Wood P.R. Purification and characterization of major antigens from a Mycobacterium bovis culture filtrate. Infect Immun 59 3 (1991) 800-807
161. Dobos K.M., Swiderek K., Khoo K.H., Brennan P.J., and Belisle J.T. Evidence for glycosylation sites on the 45-kilodalton glycoprotein of Mycobacterium tuberculosis. Infect Immun 63 8 (1995) 2846-2853
162. Skinner M.A., Buddle B.M., Wedlock D.N., Keen D., deLisle G.W., Tascon R.E., et al. A DNA prime-Mycobacterium bovis BCG boost vaccination strategy for cattle induces protection against bovine tuberculosis. Infect Immun 71 9 (2003) 4901-4907
163. Kumar P., Amara R.R., Challu V.K., Chadda V.K., and Satchidanandam V. The Apa protein of Mycobacterium tuberculosis stimulates gamma interferon-secreting CD4+ and CD8+ T cells from purified protein derivative-positive individuals and affords protection in a guinea pig model. Infect Immun 71 4 (2003) 1929-1937
164. Horn C., Namane A., Pescher P., Riviere M., Romain F., Puzo G., et al. Decreased capacity of recombinant 45/47-kDa molecules (Apa) of Mycobacterium tuberculosis to stimulate T lymphocyte responses related to changes in their mannosylation pattern. J Biol Chem 274 45 (1999) 32023-32030
165. Romain F., Horn C., Pescher P., Namane A., Riviere M., Puzo G., et al. Deglycosylation of the 45/47-kilodalton antigen complex of Mycobacterium tuberculosis decreases its capacity to elicit in vivo or in vitro cellular immune responses. Infect Immun 67 11 (1999) 5567-5572
166. Sutcliffe I.C., and Harrington D.J. Lipoproteins of Mycobacterium tuberculosis: an abundant and functionally diverse class of cell envelope components. FEMS Microbiol Rev 28 5 (2004) 645-659
167. Braibant M., Gilot P., and Content J. The ATP binding cassette (ABC) transport systems of Mycobacterium tuberculosis. FEMS Microbiol Rev 24 4 (2000) 449-467
168. Tanghe A., Lefevre P., Denis O., D'Souza S., Braibant M., Lozes E., et al. Immunogenicity and protective efficacy of tuberculosis DNA vaccines encoding putative phosphate transport receptors. J Immunol 162 2 (1999) 1113-1119
169. da Fonseca D.P., Frerichs J., Singh M., Snippe H., and Verheul A.F. Induction of antibody and T-cell responses by immunization with ISCOMS containing the 38-kilodalton protein of Mycobacterium tuberculosis. Vaccine 19 1 (2000) 122-131
170. Falero-Diaz G., Challacombe S., Banerjee D., Douce G., Boyd A., and Ivanyi J. Intranasal vaccination of mice against infection with Mycobacterium tuberculosis. Vaccine 18 28 (2000) 3223-3229 1
171. D'Souza S., Rosseels V., Denis O., Tanghe A., De Smet N., Jurion F., et al. Improved tuberculosis DNA vaccines by formulation in cationic lipids. Infect Immun 70 7 (2002) 3681-3688
172. Piddington D.L., Fang F.C., Laessig T., Cooper A.M., Orme I.M., and Buchmeier N.A. Cu, Zn superoxide dismutase of Mycobacterium tuberculosis contributes to survival in activated macrophages that are generating an oxidative burst. Infect Immun 69 8 (2001) 4980-4987
173. Harboe M., Wiker H.G., Ulvund G., Lund-Pedersen B., Andersen A.B., Hewinson R.G., et al. MPB70 and MPB83 as indicators of protein localization in mycobacterial cells. Infect Immun 66 1 (1998) 289-296
174. Harboe M., Whelan A.O., Ulvund G., McNair J., Pollock J.M., Hewinson R.G., et al. Generation of antibodies to the signal peptide of the MPT83 lipoprotein of Mycobacterium tuberculosis. Scand J Immunol 55 1 (2002) 82-87
175. Harboe M., Nagai S., Wiker H.G., Sletten K., and Haga S. Homology between the MPB70 and MPB83 proteins of Mycobacterium bovis BCG. Scand J Immunol 42 1 (1995) 46-51
176. Hewinson R.G., Michell S.L., Russell W.P., McAdam R.A., and Jacobs Jr. W.R. Molecular characterization of MPT83: a seroreactive antigen of Mycobacterium tuberculosis with homology to MPT70. Scand J Immunol 43 5 (1996) 490-499
177. Ulstrup J.C., Jeansson S., Wiker H.G., and Harboe M. Relationship of secretion pattern and MPB70 homology with osteoblast-specific factor 2 to osteitis following Mycobacterium bovis BCG vaccination. Infect Immun 63 2 (1995) 672-675
178. Michell S.L., Whelan A.O., Wheeler P.R., Panico M., Easton R.L., Etienne A.T., et al. The MPB83 antigen from Mycobacterium bovis contains O-linked mannose and (1 → 3)-mannobiose moieties. J Biol Chem 278 18 (2003) 16423-16432
179. Garbe T., Harris D., Vordermeier M., Lathigra R., Ivanyi J., and Young D. Expression of the Mycobacterium tuberculosis 19-kilodalton antigen in Mycobacterium smegmatis: immunological analysis and evidence of glycosylation. Infect Immun 61 1 (1993) 260-267
180. Herrmann J.L., Delahay R., Gallagher A., Robertson B., and Young D. Analysis of post-translational modification of mycobacterial proteins using a cassette expression system. FEBS Lett 473 3 (2000) 358-362
181. Lefevre P., Denis O., De Wit L., Tanghe A., Vandenbussche P., Content J., et al. Cloning of the gene encoding a 22-kilodalton cell surface antigen of Mycobacterium bovis BCG and analysis of its potential for DNA vaccination against tuberculosis. Infect Immun 68 3 (2000) 1040-1047
182. Hovav A.H., Mullerad J., Davidovitch L., Fishman Y., Bigi F., Cataldi A., et al. The Mycobacterium tuberculosis recombinant 27-kilodalton lipoprotein induces a strong Th1-type immune response deleterious to protection. Infect Immun 71 6 (2003) 3146-3154
183. Temmerman S., Pethe K., Parra M., Alonso S., Rouanet C., Pickett T., et al. Methylation-dependent T cell immunity to Mycobacterium tuberculosis heparin-binding hemagglutinin. Nat Med 10 9 (2004) 935-941
184. Parra M., Pickett T., Delogu G., Dheenadhayalan V., Debrie A.S., Locht C., et al. The mycobacterial heparin-binding hemagglutinin is a protective antigen in the mouse aerosol challenge model of tuberculosis. Infect Immun 72 12 (2004) 6799-6805
185. Sonnenberg M.G., and Belisle J.T. Definition of Mycobacterium tuberculosis culture filtrate proteins by two-dimensional polyacrylamide gel electrophoresis, N-terminal amino acid sequencing, and electrospray mass spectrometry. Infect Immun 65 11 (1997) 4515-4524
186. Okkels L.M., Muller E.C., Schmid M., Rosenkrands I., Kaufmann S.H., Andersen P., et al. CFP10 discriminates between nonacetylated and acetylated ESAT-6 of Mycobacterium tuberculosis by differential interaction. Proteomics 4 10 (2004) 2954-2960
187. Brodin P., Rosenkrands I., Andersen P., Cole S.T., and Brosch R. ESAT-6 proteins: protective antigens and virulence factors?. Trends Microbiol 12 11 (2004) 500-508